Invesco Ltd. Lowers Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)

Invesco Ltd. reduced its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 93.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,661 shares of the company's stock after selling 406,059 shares during the quarter. Invesco Ltd.'s holdings in Immunome were worth $283,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of IMNM. Charles Schwab Investment Management Inc. lifted its stake in Immunome by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company's stock valued at $4,856,000 after buying an additional 14,775 shares during the period. Magnus Financial Group LLC grew its holdings in shares of Immunome by 107.8% during the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock worth $569,000 after buying an additional 27,777 shares in the last quarter. Scharf Investments LLC bought a new position in shares of Immunome during the 4th quarter worth approximately $471,000. Three Bridge Wealth Advisors LLC acquired a new stake in Immunome in the 4th quarter valued at $293,000. Finally, Barclays PLC raised its holdings in Immunome by 125.9% during the third quarter. Barclays PLC now owns 105,886 shares of the company's stock worth $1,547,000 after acquiring an additional 59,016 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

Immunome stock traded down $0.87 during mid-day trading on Tuesday, reaching $7.63. The stock had a trading volume of 1,480,896 shares, compared to its average volume of 907,300. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $16.81. The firm has a market capitalization of $663.90 million, a PE ratio of -0.94 and a beta of 2.00. The stock's 50-day simple moving average is $7.85 and its 200-day simple moving average is $10.04.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. On average, research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CTO Philip Tsai purchased 12,300 shares of the business's stock in a transaction dated Monday, March 24th. The stock was bought at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares of the company's stock, valued at $280,386. The trade was a 58.57 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Clay B. Siegall acquired 137,100 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $7.29 per share, with a total value of $999,459.00. Following the acquisition, the chief executive officer now owns 806,736 shares in the company, valued at $5,881,105.44. The trade was a 20.47 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 156,400 shares of company stock valued at $1,160,495. 8.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently commented on IMNM. Lake Street Capital assumed coverage on Immunome in a report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price target for the company. Lifesci Capital initiated coverage on Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price target on the stock. Wedbush restated an "outperform" rating and set a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. Finally, Stephens reaffirmed an "overweight" rating and issued a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $25.33.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.